Notes to editors
SOURCES OF FUNDING: The study was sponsored mostly by Biotronik GmbH.
DISCLOSURES: Ownership Interest in Marrek, Inc., Cardiac Designs. Contracted Research with Biosense Webster, Medtronic, St Jude Medical, Boston Scientific. Consulting fees from Biotronik, Preventice.
References and notes
1The study "Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation: the CASTLE-AF trial" will be presented during:
* The press conference Hot Line - Late Breaking Clinical Trials 1 on Sunday 27 August from 8:00 to 9:00.
* The session Hot Line - Late Breaking Clinical Trials 1 on Sunday 27 August from 11:00 to 12:30 in Barcelona - Main Auditorium.
2Left ventricular dysfunction constitutes the final pathway for a host of cardiac disorders. AF is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.
3Catheter Ablation versus Standard conventional Treatment in patients with LEft ventricular dysfunction and Atrial Fibrillation (CASTLE-AF)
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
About ESC Congress 2017
ESC Congress is the world's largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at firstname.lastname@example.org.